Vemurafenib for BRAFV600E- positive metastatic papillary thyroid cancer

被引：3
|
作者：
Huillard, Olivier [1 ]
Tenenbaum, Florence [2 ]
Clerc, Jerome [2 ]
Goldwasser, Francois [1 ]
Groussin, Lionel [3 ]
机构：
[1] Paris Descartes Univ, Cochin Hosp, AP HP, Dept Med Oncol, F-75014 Paris, France
[2] Paris Descartes Univ, Cochin Hosp, AP HP, Dept Nucl Med, F-75014 Paris, France
[3] Paris Descartes Univ, Cochin Hosp, AP HP, Dept Endocrinol, F-75014 Paris, France
来源：
LANCET ONCOLOGY | 2016年 / 17卷 / 11期
关键词：
IODINE;
D O I：
10.1016/S1470-2045(16)30499-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E468 / E468
页数：1
相关论文
共 50 条
  • [41] A Novel Cellular Model of Pediatric and Adult BRAFV600E-mutated Papillary Thyroid Cancer
    O'Neill, Alison
    Medrano, Victoria Casado
    Branigan, Grace Purvis
    Salwen, Madeleine
    Bauer, Andrew
    Franco, Aime
    HORMONE RESEARCH IN PAEDIATRICS, 2022, 95 (SUPPL 1): : 241 - 242
  • [42] Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
    Huang, Shuhui
    Qi, Mengfang
    Tian, Tian
    Dai, Hongyuan
    Tang, Yuan
    Huang, Rui
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [43] Association Between Obesity and BRAFV600E Mutation Status in Patients with Papillary Thyroid Cancer
    Lee, Jandee
    Lee, Cho Rok
    Ku, Cheol Ryong
    Kang, Sang-Wook
    Jeong, Jong Ju
    Shin, Dong Yeob
    Nam, Kee-Hyun
    Jung, Sang Geun
    Lee, Eun Jig
    Chung, Woong Youn
    Jo, Young Suk
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S683 - S690
  • [44] Association Between Obesity and BRAFV600E Mutation Status in Patients with Papillary Thyroid Cancer
    Jandee Lee
    Cho Rok Lee
    Cheol Ryong Ku
    Sang-Wook Kang
    Jong Ju Jeong
    Dong Yeob Shin
    Kee-Hyun Nam
    Sang Geun Jung
    Eun Jig Lee
    Woong Youn Chung
    Young Suk Jo
    Annals of Surgical Oncology, 2015, 22 : 683 - 690
  • [45] Impact of BRAFV600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer
    Trybek, Tomasz
    Walczyk, Agnieszka
    Gasior-Perczak, Danuta
    Palyga, Iwona
    Mikina, Estera
    Kowalik, Artur
    Hincza, Kinga
    Kopczynski, Janusz
    Chrapek, Magdalena
    Gozdz, Stanislaw
    Kowalska, Aldona
    ENDOCRINOLOGY, 2019, 160 (10) : 2328 - 2338
  • [46] Can Suspicious Ultrasound Features Predict BRAFV600E Status in Papillary Thyroid Cancer?
    Khadra, Helmi
    Deniwar, Ahmed
    Mohsin, Khuzema
    Monlezun, Dominique
    Kandil, Emad
    EUROPEAN THYROID JOURNAL, 2018, 7 (04) : 205 - 210
  • [47] Postnatal Expression of BRAFV600E Does Not Induce Thyroid Cancer in Mouse Models of Thyroid Papillary Carcinoma
    Shimamura, Mika
    Nakahara, Mami
    Orim, Florence
    Kurashige, Tomomi
    Mitsutake, Norisato
    Nakashima, Masahiro
    Kondo, Shinji
    Yamada, Masanobu
    Taguchi, Ryo
    Kimura, Shioko
    Nagayama, Yuji
    ENDOCRINOLOGY, 2013, 154 (11) : 4423 - 4430
  • [48] Unresectable or metastatic BRAFV600-Mutation- positive Melanoma Vemurafenib Therapeutic offers good prospects
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (06) : 330 - 330
  • [49] Cobimetinib Plus Vemurafenib: A Review in BRAFV600 Mutation-Positive Unresectable or Metastatic Melanoma
    Keating, Gillian M.
    DRUGS, 2016, 76 (05) : 605 - 615
  • [50] Cobimetinib Plus Vemurafenib: A Review in BRAFV600 Mutation-Positive Unresectable or Metastatic Melanoma
    Gillian M. Keating
    Drugs, 2016, 76 : 605 - 615
12345